Capricor Therapeutics (NASDAQ: CAPR) revenue
Capricor Therapeutics reported revenue of $0.0m for fiscal 2025, 100.0% less than in fiscal 2024 ($22.3m).
Capricor Therapeutics's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2023. The biggest drop was in fiscal 2020, −69.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | −100.0% | −$108.1m | — |
| 2024 | $22.3m | −11.5% | −$42.6m | −191.1% |
| 2023 | $25.2m | +886.8% | −$24.1m | −95.6% |
| 2022 | $2.6m | +941.8% | −$29.7m | −1,163.9% |
| 2021 | $0.2m | −21.1% | −$20.9m | −8,549.9% |
| 2020 | $0.3m | −69.1% | −$13.7m | −4,412.6% |
| 2019 | $1.0m | −39.9% | −$7.7m | −769.5% |
| 2018 | $1.7m | −37.3% | −$15.3m | −917.0% |
| 2017 | $2.7m | −33.3% | −$12.9m | −482.4% |
| 2016 | $4.0m | — | −$17.0m | −424.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Capricor Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Capricor Therapeutics ranks 405th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Capricor Therapeutics, −100.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 403rd | Amylyx Pharmaceuticals | $0.0m | −100.0% |
| 404th | Artiva Biotherapeutics | $0.0m | −100.0% |
| 405th | Capricor Therapeutics | $0.0m | −100.0% |
| 406th | Compass Therapeutics | $0.0m | −100.0% |
| 407th | Denali Therapeutics | $0.0m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Capricor Therapeutics
- How much revenue did Capricor Therapeutics make in fiscal 2025?
- Capricor Therapeutics reported revenue of $0.0m for fiscal 2025, compared with $22.3m in fiscal 2024.
- What was the best year for revenue at Capricor Therapeutics?
- Of its last 10 fiscal years, fiscal 2023, with $25.2m.
- Where does Capricor Therapeutics rank in its sector by revenue?
- It ranks 405th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Capricor Therapeutics come from?
- From the annual report (Form 10-K) that Capricor Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Capricor Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Capricor Therapeutics: the Capricor Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.